Free tool
Oncology stocks
We cover 103 companies grouped under the Oncology theme. The median market value in the group is $692.32M. Across the group, the median move over the past trading day is +2.43%. 64% of the 101 with a 200-day average trade above it. Price change over the past year runs from −53.5% to +264.6% across the middle 80 percent of the group, with a median of +35.4%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
103 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% | Oct 29, 2026 |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% | Oct 30, 2026 |
| BMY | Bristol-Myers Squibb Company | $67.92 | +8.57% | +28.36% | +49.31% | Oct 29, 2026 |
| RVMD | Revolution Medicines, Inc. | $211.38 | +12.39% | +167.50% | +492.60% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $376.37 | +15.49% | +21.01% | +21.95% | Nov 5, 2026 |
| BNTX | BioNTech SE | $114.05 | +25.21% | +17.95% | +8.55% | Nov 3, 2026 |
| INCY | Incyte Corporation | $129.72 | +9.13% | +27.90% | +53.04% | Oct 27, 2026 |
| GMAB | Genmab A/S | $34.36 | +19.31% | +7.98% | +41.34% | Nov 5, 2026 |
| EXEL | Exelixis, Inc. | $56.72 | +1.63% | +30.15% | +49.66% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $13.36 | +1.95% | −23.74% | −49.14% | Oct 19, 2026 |
| LNTH | Lantheus Holdings, Inc. | $100.87 | −6.63% | +49.95% | +79.61% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $36.80 | −9.00% | +5.93% | +212.13% | Nov 3, 2026 |
| ERAS | Erasca, Inc. | $17.76 | −5.88% | +394.71% | +1016.98% | Nov 11, 2026 |
| RLAY | Relay Therapeutics, Inc. | $20.57 | +10.35% | +151.47% | +486.04% | Nov 5, 2026 |
| CELC | Celcuity Inc. | $92.27 | +12.16% | −8.23% | +87.35% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $24.51 | −8.27% | +174.47% | +264.73% | Nov 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $31.57 | +13.40% | +35.55% | +211.03% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $29.39 | +30.14% | +41.14% | +196.22% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $14.09 | +29.98% | +223.91% | +637.70% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $26.95 | +15.02% | +49.22% | +178.70% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $7.10 | +6.61% | −17.25% | +146.53% | Nov 2, 2026 |
| URGN | UroGen Pharma Ltd. | $46.36 | +11.82% | +104.14% | +150.59% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% | Nov 4, 2026 |
| NBTX | Nanobiotix S.A. | $41.51 | +3.31% | +87.57% | +321.42% | Sep 29, 2026 |
| NVCR | NovoCure Limited | $17.62 | +3.46% | +34.30% | +50.60% | Oct 29, 2026 |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% | Nov 5, 2026 |
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% | Nov 5, 2026 |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% | Nov 5, 2026 |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% | Nov 4, 2026 |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% | Nov 13, 2026 |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% | Nov 2, 2026 |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% | Nov 10, 2026 |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% | Nov 16, 2026 |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% | Nov 5, 2026 |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% | Nov 12, 2026 |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% | Nov 5, 2026 |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% | Nov 17, 2026 |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% | Nov 5, 2026 |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% | Nov 3, 2026 |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% | Nov 5, 2026 |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% | Nov 3, 2026 |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% | Nov 12, 2026 |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% | Nov 4, 2026 |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% | Nov 9, 2026 |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% | Nov 3, 2026 |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% | Nov 12, 2026 |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% | Nov 3, 2026 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% | Nov 11, 2026 |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% | Nov 12, 2026 |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% | Nov 5, 2026 |
| GUD.TO | Knight Therapeutics Inc. | 9.75 CAD | −0.71% | +64.97% | +49.08% | Nov 5, 2026 |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% | Nov 12, 2026 |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% | Nov 3, 2026 |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% | Nov 12, 2026 |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% | Nov 4, 2026 |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% | Nov 3, 2026 |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% | Nov 11, 2026 |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% | Nov 5, 2026 |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% | Nov 5, 2026 |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% | Nov 5, 2026 |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% | Nov 12, 2026 |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% | Nov 5, 2026 |
| FRX.TO | Fennec Pharmaceuticals Inc. | 15.49 CAD | +5.73% | +48.80% | +27.38% | Nov 12, 2026 |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% | Nov 5, 2026 |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% | Nov 9, 2026 |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% | Oct 29, 2026 |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% | Nov 5, 2026 |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% | Nov 6, 2026 |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% | Nov 12, 2026 |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% | Nov 12, 2026 |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% | Nov 2, 2026 |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% | Sep 17, 2026 |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% | Nov 10, 2026 |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% | Nov 5, 2026 |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% | Nov 10, 2026 |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% | Nov 13, 2026 |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% | Nov 5, 2026 |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% | Sep 9, 2026 |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% | Nov 12, 2026 |
| HBP.TO | Helix BioPharma Corp. | 1.99 CAD | +38.19% | −17.08% | +35.37% | Oct 29, 2026 |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% | Nov 16, 2026 |
| CRDF | Cardiff Oncology, Inc. | $1.02 | +21.43% | −61.65% | −53.85% | Nov 12, 2026 |
| OSTX | OS Therapies Incorporated | $1.65 | +7.84% | +23.13% | −24.66% | Nov 16, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $1.14 | +5.56% | −8.80% | −23.49% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.31 | +10.59% | +6.10% | −8.10% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $0.32 | −29.76% | −74.36% | −76.59% | Nov 3, 2026 |
| IMMP | Immutep Limited | $0.38 | +0.50% | −87.05% | −77.54% | Sep 2, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $0.89 | +96.47% | +37.98% | −35.04% | Oct 30, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $1.92 | −72.92% | −73.30% | −69.57% | Nov 3, 2026 |
| KYNB | Kyntra Bio, Inc. | $8.10 | +14.89% | −11.57% | −23.80% | Nov 9, 2026 |
| BYSI | BeyondSpring Inc. | $0.72 | −38.44% | −55.27% | −60.43% | Nov 12, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | 0.47 CAD | +36.23% | −53.00% | −58.77% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $2.18 | −21.86% | −29.90% | −52.30% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $2.54 | +4.96% | −26.80% | −45.96% | Nov 12, 2026 |
| BFRI | Biofrontera Inc. | $1.51 | +43.81% | +108.28% | +63.77% | Nov 11, 2026 |
| TPST | Tempest Therapeutics, Inc. | $1.11 | +18.72% | −62.37% | −89.50% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $1.74 | +20.83% | −11.22% | −31.23% | Nov 5, 2026 |
| BLRX | BioLineRx Ltd. | $2.85 | +1.06% | +1.79% | −25.97% | Aug 31, 2026 |
| PDSB | PDS Biotechnology Corporation | $0.22 | −68.04% | −73.41% | −82.96% | Nov 12, 2026 |
| LNAI | Lunai Bioworks Inc. | $2.20 | −1.35% | −71.71% | −87.99% | Sep 28, 2026 |
| BCAB | BioAtla, Inc. | $3.26 | −4.12% | −87.79% | −81.69% | Nov 12, 2026 |
| CRIS | Curis, Inc. | $1.59 | −66.10% | +62.24% | −3.64% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.